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Abstract
The integration of genomic and epigenomic data is an increasingly popular approach for studying the complex
mechanisms driving cancer development. We have developed a method for evaluating both methylation and copy
number from high-density DNA methylation arrays. Comparing copy number data from Infinium HumanMethylation450
BeadChips and SNP arrays, we demonstrate that Infinium arrays detect copy number alterations with the sensitivity of
SNP platforms. These results show that high-density methylation arrays provide a robust and economic platform for
detecting copy number and methylation changes in a single experiment. Our method is available in the ChAMP
Bioconductor package: http://www.bioconductor.org/packages/2.13/bioc/html/ChAMP.html.
Background
Copy number alterations (CNAs) have been implicated
in the development and progression of many human
malignancies, including prostate, bladder and breast can-
cer [1-4]. Since first described in the late 1990s, many
platforms have been developed for assessing alterations
in genomic copy number at an ever increasing resolution
[5-9]. The latest version of copy number variation arrays
can interrogate over one million loci, and have the abil-
ity to detect genomic alterations ranging from approxi-
mately 4 kb to over 2 Mb [10-13]; they are, however,
limited in the size of small alterations detectable, due to
the distance between loci interrogated (Table 1). As a re-
sult, many small/micro-deletions encompassing single
genes may not be detectable [9].
In parallel, arrays designed to interrogate epigenetic al-
terations, particularly DNA CpG methylation, have been
developed. These arrays were initially designed based on
immunoprecipitation (MeDIP) or enzymatic digestion
followed by hybridization to a bacterial artificial chromo-
some or oligonucleotide CpG island array [14,15]. Subse-
quently, there has been a move towards arrays designed
on the premise of SNP detection arrays, and applied to
bisulfite converted DNA [16-18]. Probes are designed
for the detection of C/T alterations based on the conver-
sion of unmethylated cytosine with bisulfite. The relative
ratio of methylated (C) to unmethylated (T) residues is
then used to define the methylation state of a particular
locus [16].
The integration of genomic and epigenomic data from
the same sample is becoming increasingly popular as we
try to garner a greater understanding of the complex
mechanisms driving the development and progression of
cancers. Although at present arrays still prove the most
cost-effective method of assessing both copy number and
DNA methylation state, this interest in integrating multiple
data sets means a significant increase in costs associated
with these projects. Huge international efforts are currently
underway through the International Cancer Genome Con-
sortium (ICGC) and the Cancer Genome Atlas (TCGA)
projects to produce genomic and epigenomic data on a
huge number of human cancers. At present these data are
generated on separate array platforms, with over 6,200
SNP arrays and 6,300 methylation arrays used to date to
generate genomic and epigenomic profiles from the same
sample. This, therefore, not only doubles the cost but also
the amount of specimen used. The latter is particularly im-
portant when considering the potential effects of tumor
heterogeneity on disease development, where subtle areas
of a tumor are genetically and epigenetically different,
which may ultimately confer a different phenotypic trait,
such as differing metastatic potential [19].
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We therefore sought to assess if the Infinium Human-
Methylation450 BeadChips (the methylation array of choice
for the ICGC and TCGA) could be used to define regions
of CNA as well as sites of aberrant CpG methylation. It has
already been shown, for low density methylation arrays and
high resolution whole genome bisulfite sequencing, that
changes in genomic content do not impact on the ability of
these arrays to accurately define the methylation state for
individual loci and that these technologies also have poten-
tial utility in detecting CNAs [20-22]. As the Infinium
methylation arrays are, in essence, SNP arrays, providing
high density coverage of the genome, the question is do
they have the sensitivity and specificity to detect CNAs with
the same accuracy as existing technologies. This will not
only allow analysis and ultimately the integration of both
epigenetic and copy number from exactly the same DNA
specimen, potentially important when considering the ef-
fects of tumor heterogeneity on disease development and
progression [19,23], but will also significantly reduce the
cost of integrated epigenomic cancer studies looking to in-
corporate both data types.
Results and discussion
Influence of copy number alteration on methylation state
Prior to evaluating whether the Infinium array could detect
CNAs, we first sought to assess whether alterations in gen-
omic content influenced the methylation state inferred by
the Infinium HumanMethylation450 BeadChips. Previous
analysis of similar low density Infinium type arrays
(GoldenGate) have shown that changes in DNA methyla-
tion are unaffected by copy number (CN) state [20].
Figure 1 shows the average beta value (methylation score)
for all potential sites on the Infinium array as a function
of CN determined from Affymetrix SNP6.0 or Illumina
CytoSNP arrays from 11 chondrosarcoma and 74 glio-
blastoma multiforme (GBM) tumors. It also shows the
average beta value for all potential sites on the Infinium
array as a function of CN determined from an Affymetrix
SNP6.0 array from 144 bladder cancer and 178 prostate
cancer samples, respectively.
These data show that CN has little impact on methy-
lation (Figure 1) in either series at regions of heterozy-
gous loss or single copy gains when compared with
regions of normal CN. However, there does appear to
be an association when assessing homozygous deletion
and amplification (P < 2.2e-16), where a significant
negative correlation is observed with both data sets.
An association with beta value and homozygous loss
was as expected as low/no signal does not allow accurate
assessment of methylation; in fact, most probes in these
regions fail to pass the Illumina signal quality detection
P-value (defined by the comparison of signal from the
target compared to that of negative controls (Illumina
user manual)), and are removed in standard methylation
analyses. Unexpectedly, however, a significant negative
correlation was observed between regions of SNP array
amplification and reduced beta values in all data sets.
Unlike in regions of deletion, over 97% of probes in
regions of amplification pass the detection P-value. On
closer inspection, this negative correlation appears to
be driven by the Infinium probe distribution. A higher
proportion of probes in regions of focal amplification
are located in CpG islands, which are predominately
unmethylated, when compared with regions of normal
ploidy [12,13,24]. Separating the Infinium probes within
regions of amplification into CpG island-associated ver-
sus non-CpG island-associated confirmed this (Figure S1
in Additional file 1), with CpG island-associated probes
having a mean beta of 0.28 compared with 0.62 for non-
CpG island-associated probes (similar beta values are
observed if regions of no change and gain are partitioned
in a similar fashion). The inherent complex dynamics
between CN and methylation means it is difficult to dis-
entangle biology from systematic biases.
Array artifact removal
Furthermore, as with other array-based platforms, tech-
nical artifacts, such as batch effects and genomic wave,
may impinge on the accurate profiling of CNA form the
Infinium arrays. A genomic-wave artifact, a probe effect
that correlates with surrounding genomic GC content
and is commonly observed in other comparative gen-
omic hybridization and SNP array platforms, and is also
manifest on the Infinium arrays [25,26]. In order to help
negate any effects of local CG content in calling CNAs,
we performed a loess correction prior to CNA analysis,
which estimates and removes the wave effects [25].
In a similar fashion, batch effects have been shown to
have a substantial effect on high throughput array-based
platforms, and are particularly apparent with the Infinium
arrays, particularly when considering scale projects, such
Table 1 Genomic probe distribution
Affymetrix SNP 6.0 Illumina CytoSNP Illumina 450 K methylation array
Number of probes 945,806 296,715 485,577
Median intermarker distance (kb) 2.3 6.1 0.35
Mean intermarker distance (kb) 3.0 10.8 5.8
Number of probes, mean and median intermarker distance interrogating copy number alterations from Affymetrix SNP 6.0, Illumina CytoSNP and Infinium
HumanMethylation450 BeadChip.
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as the TCGA [27,28]. In order to help reduce variance at-
tributed to batch as opposed to biological influence, we
also incorporated batch effect removal with the ComBat
function [29]. Batch effect removal significantly improved
the correlation between replicate samples across differing
batches (Figure S2 in Additional file 1): uncorrected R2 =
0.77 compared to batch-corrected R2 = 0.97. The correl-
ation of replicate samples within a single array was R = 0.99,
suggesting array position does not unduly affect signal in-
tensity. All subsequent analysis where carried out on wave-
and batch-corrected data (Figure S2 in Additional file 1).
It is well documented that the different Infinium assay
designs (type I and type II) show considerable probe ef-
fects [16,30]. For example, when assessing methylation,
the beta values derived from Infinium II probes were less
accurate and reproducible than those obtained from Infi-
nium I probes [30]; it has therefore been suggested (at
least for methylation analysis) that the differing probe
types be treated independently. We initially took this ap-
proach when utilizing these arrays to assess CN, as the
intensities of the two probe types also show considerable
differences [16,30].
Copy number alteration profiling using Infinium
methylation arrays
Our initial motivation was to assess if the Infinium
HumanMethylation450 BeadChips could provide infor-
mation on genomic rearrangements with a level of ac-
curacy comparable to current gold standard SNP arrays.
As the Infinium arrays are, in essence, SNP arrays, with
probes designed to interrogate the relative ratio of a
methylated to unmethylated (C to T) template in bisul-
fite converted DNA, and as the methylation state (beta
value) is defined by a relative ratio of methylated probe
signal intensity to the total signal intensity of both meth-
ylated and unmethylated probes, it is logical to expect
that these arrays may also allow assessment of CN. If
total (unmethylated plus methylated) probe intensity is
representative of CN, then the simplest of CN changes,
that is, differences in the sex chromosomes between
males and females, should be clearly detectable. Figure 2
shows the total signal intensities of the autosomal and
sex chromosomes for normal reference DNA and 11
chondrosarcoma patients. These data clearly show a sig-
nificant (P < 2.2e-16) difference between the autosomal
Figure 1 Association of methylation state with copy number. Box plots showing the influence of changing genomic content on methylation
state (average beta value) inferred from SNP (CytoSNP and Affymetrix SNP6.0) and Infinium arrays, respectively, for (A) chondrosarcoma, (B)
glioblastoma multiforme, (C) bladder cancer and (D) prostate cancer.
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chromosomes and sex chromosomes and that the Infi-
nium methylation arrays can potentially detect single
copy alterations.
We subsequently assessed the relationship between
Infinium probe intensity and differing CNA states de-
fined by SNP array from an in-house series of matched
Infinium and CytoSNP arrays along with 386 samples
from the TCGA project, representing three tumor types,
GBM, prostate cancer and bladder cancer. As expected,
regression coefficients confirmed that the mean Infinium
signal intensity increases monotonically with CNA state
(Figure 3), with a significant difference (P <0.0001) in
mean Infinium signal at all levels of CN states, except
for putative homo- and heterozygous loss in the GBM
samples, where no difference is observed (P = 0.76). It
should be noted that, for both sample cohorts, there
were sufficient Infinium probes within regions of poten-
tial homozygous/heterozygous loss (defined on the SNP
arrays (CytoSNP and SNP6.0)) to allow comparison, and
while in theory no signal should be detectable when no
copies exist (heterozygous loss), no two probes from the
Infinium or SNP arrays overlap the same genomic loci,
and that there is a stochastic component to both the as-
signment of CN and measurement of intensity that may
account for this lack of correlation in regions of hetero-
zygous/homozygous loss.
Finally, we sought to define CN profiles from Infinium
array data. CNAs were identified using circular binary
segmentation in the Bioconductor package DNAcopy
[31]. We initially analyzed both probe types independ-
ently and evaluated the concordance of CNAs identified.
Using the default parameters, type II probes appear to
show a higher degree of noise than the type I probes.
Despite this, the concordance of CNAs called by both
probe types (when considering large regions) is high
(97%), although this is significantly lower when consider-
ing smaller focal alterations (24%). However, this may
also somewhat reflect the differing genomic densities of
the two probe types. Comparing overlapping regions
only showed the CNA states generated from the two
probe types to be highly correlated (R2 = 0.94, range
0.48 to 0.99; Figure S3 in Additional file 1), allowing the
two probe types to be coalesced.
To confirm that CNA analysis can detect single copy
events, we compared normal reference DNA from single
male and female subjects. Figure 4 shows example CNA
profiles of reference male versus female samples, between
which a significant difference in the CN state of the sex
Figure 2 Changes in Infinium probe intensities between sex chromosomes. (A) Box plots of Infinium total signal intensities for autosomes
and sex chromosomes for male and female patients (autosome (green) and sex chromosomes (chromosome X (red), chromosome Y (blue)).
(B) Box plots of Infinium intensities for autosomes and sex chromosomes for 11 chondrosarcoma samples (females, red; males, blue).
Feber et al. Genome Biology 2014, 15:R30 Page 4 of 13
http://genomebiology.com/2014/15/2/R30
chromosomes is observed (P ≤ 0.0001), along with an ex-
ample of a highly aneuploid malignant genome. These
data indicate that the Infinium HumanMethylation450
BeadChips, when combined with circular binary segmen-
tation, can detect both single copy and potentially high
level CNAs.
Correlation between Infinium and SNP array-defined
CNAs
We next sought to assess whether the Infinium arrays
could give a robust definition of CNAs compared to the
gold standard SNP arrays for aneuploid malignant ge-
nomes. CNAs were determined from both SNP arrays as
Figure 3 Comparison of Infinium total probe intensity and changing copy number. Box plots showing the association of total probe
signal intensity from the Infinium arrays and copy number state inferred from SNP arrays for (A) chondrosarcoma, (B) glioblastoma multiforme,
(C) bladder cancer and (D) prostate cancer.
Figure 4 Normal and malignant copy number profiles. (A) CN profile for normal female versus male reference. (B) CN profile for a highly
aneuploid cancer genome (versus male reference) derived from the Infinium arrays. Individual chromosomes are shown in green/black and
segmented CN is shown in red.
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above, using the Bioconductor package DNAcopy for
GBM samples. For bladder cancer and prostate cancer
samples, processed CNA estimates were download dir-
ectly from the TCGA project.
We assessed the correlation of all 407 samples with
paired Infinium and SNP array CNA profiles. In the ma-
jority of cases, global CN profiles from the different plat-
forms appeared highly correlated with an average
correlation coefficient of 0.91, ranging from 0.29 to 0.99,
and show a similar frequency and amplitude of alter-
ations. Figure 5 shows CN profiles from a single sample
for chromosome 12 for both Illumina CytoSNP and Infi-
nium 450Methylation Bead arrays as well as an overlay
of these. It also shows the correlation between Infinium
CNA and SNP array CNA profiles for the whole genome
and for chromosome 12 (R2 = 0.96).
To assess the robustness of CNAs identified from the
Infinium arrays, we compared them with CN profiles
generated from a SNP array for matched samples. We
initially assessed the agreement of large rearrangements
(that is, alterations of >10 Mb) for both gains and losses.
This analysis showed that a total of over 94% of large
chromosomal gains and 97% of losses were identified by
both Infinium and the SNP array, suggesting that the
Infinium arrays show sufficient sensitivity to detect large
scale, predominately single copy alterations.
Copy number alteration detection sensitivity
Besides the detection of large chromosomal rearrange-
ments, we also sought to evaluate the ability of the Infinium
arrays to detect focal alterations, including small (<1 Mb)
high-level amplifications and homozygous deletions. We
initially assessed the overlap between all regions of focal
genomic alteration (<1 Mb) independent of alteration
threshold; these regions were termed candidate true posi-
tives. In total 76% of all focal regions of alterations are iden-
tified in common between the SNP and Infinium arrays. Of
those alterations showing a discrepancy between the Infi-
nium and SNP arrays, approximately 25% are identified by
the SNP array only (candidate false negative), while the
remaining approximately 75% are identified by the Infinium
array only (candidate false positive). The disparity in the call
rates between the array platforms could be attributed to the
differing array designs and the gene-centric nature of the
Infinium arrays. When the analysis is limited to regions
with sufficient probe coverage (minimum marker = 3) to
call alterations in both arrays, over 79% of common alter-
ations are detected. This resulted in an overall sensitivity of
0.71 and specificity of 0.83. To assess the performance of
the Infinium array to detect CNAs with the same accuracy
as SNP arrays, we plotted the binomial probability of an al-
teration being called a true positive versus alteration cover-
age at differing alteration thresholds (that is, gain, loss,
amplification and deletion) across all 407 paired SNP Infi-
nium array comparisons (Figure 6). This confirmed that
the Infinium arrays show a good level of accuracy in de-
tecting alterations at all levels of alteration across multiple
studies (Table 2).
Copy number alteration resolution
As highlighted above, Infinium arrays define a significant
number of CNAs that are not present in the SNP array
data (candidate false positives). We sought to determine
whether these alterations are entirely down to array design
Figure 5 Comparison of Infinium and SNP copy number profiles. CN profiles for chromosome 12 for a single chondrosarcoma sample using
(A) Infinium array, (B) CytoSNP and (C) combined Infinium and CytoSNP. (D) Scatter plot showing the correlation between Infinium CN and SNP
array CN states from matched samples. (E) Scatter plot of Infinium and SNP array CNA states for chromosome 12 only.
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or whether they were artifacts. On close inspection, most
of these false positives (92%) appear to be regions devoid
of sufficient probes to call a change on the SNP arrays.
For example, Figure 7 shows LOH (loss of hetrozygosity)
of the entire chromosome 9 by both SNP and Infinium ar-
rays, along with the focal, potential homozygous deletion
of a further four regions, including the loci encompassing
the tumor suppressor gene CDKN2A. Three of the four
homozygous deletions are identified by both array types,
apart from an approximately 10 kb region (Figure 7) not
detected by the CytoSNP array. This region (log2R = -2.7)
contains 24 probes on the Infinium arrays and appears to
span approximately 34 kb (first 3 exons) and 1.2 kb up-
stream of PTCH1 only (9 probes in the remaining 44 kb
of PTCH1 showed heterozygous loss only, log2R = -0.36,
similar to the remainder of Chr9). However, this region is
represented by only a single probe on the CytoSNP array
(nearest neighbors 5 = 7.34 kb and 3 = 6.99 kb).
Quantitative PCR validation confirmed the heterozygous
deletion of this region in PTCH1 (Figure S4 in Additional
file 1). Similarly, Figure 4 shows the homozygous deletion
of a small region centered on GSTT1; homozygous dele-
tion of this gene has been associated with increased sus-
ceptibility to many different cancer types, including
prostate cancer, renal cancers and osteosarcoma [32-35].
The Infinium data indicate this deletion spans approxi-
mately 12 kb and contains GSTT1 and a small proportion
of the neighboring LOC391322 only (Figure 8). This re-
gion also contains a single probe from the Affymetrix
SNP6.0 array and would be undetectable by the Illumina
CytoSNP arrays (Figure 8). Quantitative PCR validated the
homozygous deletion of GSTT1 (Figure S4 in Additional
file 1). Although we have not mapped the full extent of
these deletions, these data highlight the potential utility of
these arrays to identify novel small alterations that are not
detectable with existing SNP array platforms.
We further validated CNAs identified by the Infinium
arrays with the targeted exome-sequencing of key cancer
genes [36]. This analysis revealed greater than 90% con-
cordance between alterations identified by Infinium CNA
profiling and targeted exome sequencing (Figure S5 in
Additional file 1). Of overlapping loci, 45 alterations were
identified from Infinium CNA profiling with a false posi-
tive rate of 8%, and a similar false negative rate (8.8%)
[36], further highlighting that the Infinium arrays provide
a reliable, robust and cost-effective method of identifying
CNAs in human cancers.
Conclusion
There is increasing interest in the integration of genomic
and epigenomic data from the same DNA specimen in
order to provide greater insight into disease processes. It
is particularly intriguing to integrate genomic CN and
DNA methylation data, which may allow the identifica-
tion of synergistic mechanisms for the inactivation of
tumor suppressor genes or the activation of oncogenic
pathways [3]. However, the integration and ultimately
the interpretation of these integrated datasets are both
costly and challenging if carried out separately.
Here we sought to evaluate whether the Infinium
HumanMethylation450 BeadChip could be utilized to
determine CNAs as well as epigenetic alterations. Ini-
tially, we sought to confirm that the methylation state
inferred by the Infinium HumanMethylation450 Bead-
Chip was not biased by altered CN state. We show there
is little bias when comparing normal (two copies) to het-
erozygous loss (one copy) or single copy gain (three cop-
ies). However, there does appear to be a correlation at
loci of complete genomic loss, potential homozygous de-
letion (more than one copy) and amplification (more
than four copies). Association of methylation and CNA
state with homozygous loss is unsurprising and has little
Figure 6 Coverage plots of candidate true positives to assess
the sensitivity and specificity of alterations defined by the
Infinium arrays. At each alteration threshold (deletion, blue; loss,
red; gain, black; amplification, green) we counted the alterations that
overlap between matched arrays. The number of overlapping
regions (candidate true positives). Dotted lines represent 95%
confidence intervals.
Table 2 Infinium sensitivity and specificity
Sensitivity
Deletion Loss Gain Amplification
Chondrosarcoma 0.83 0.91 0.89 0.69
GBM 0.97 0.85 0.87 0.75
Bladder cancer 0.62 0.81 0.79 0.67
Prostate cancer 0.6 0.81 0.85 0.63
The sensitivity and specificity of CNAs identified between SNP array and
Infinium methylation arrays for four tumor types across a range of
alteration types.
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impact on methylation analysis per se as these loci are
generally removed from methylation analysis due to sig-
nal intensities indistinguishable from background (low
detection P-value). However, it may represent a con-
founding factor effect when comparing methylation in
samples with and without CNA. For example, a tumor
suppressor deleted in a proportion of samples may be
hypermethylated in others, but in many Infinium methy-
lation array analysis pipelines this information will be
lost due to the removal of missing data. This highlights
the importance of integrated analysis using both CNA
and methylation data. The strong negative association
between methylation state and regions of high level ampli-
fication was less anticipated, and appears to be a result of
the genomic distribution of probes as opposed to inherent
biases of the arrays. As most probes in regions of amplifi-
cation fall within CpG islands, which are predominately
unmethylated, these therefore contribute to the apparent
loss of methylation in regions of amplification.
Our primary objective was to assess whether the Infi-
nium HumanMethylation450 BeadChip could be used to
accurately assess CNAs to the same degree of reliability
and sensitivity as standard SNP array platforms, such as
the Affymetrix 6.0 SNP or Illumina CytoSNP arrays. Spe-
cifically, we compared Infinium CNA profiles from sam-
ples with matched SNP array data. Using the same
algorithm for all array types, we show that approximately
85% of all alterations were identified in both SNP and Infi-
nium arrays (when regions contain sufficient overlapping
probes). Interestingly, we see a reduced concordance when
assessing smaller alterations, with a high number of false
positive alterations identified by the Infinium arrays com-
pared to SNP platforms. The majority of these appear to
be results of differences in array design and the gene-
centric design bias of the Infinium arrays. Unlike the
standard SNP array design, with probes roughly evenly
distributed throughout the genome, the Infinium arrays
are very much gene-centric in their design, with 95% of
Figure 7 Infinium unique PTCH1 deletion. CN profiles for chromosome 9 for a single chondrosarcoma sample generated from Infinium
HumanMethylation450 BeadChip (upper panel) and CytoSNP arrays (middle panel). The Infinium array-specific deletion of PTCH1 is highlighted
(blue box).The lower panel shows the genomic organization of the Infinium unique PTCH1 region of deletion and the distribution of probes on
the Infinium methylation, CytoSNP and SNP 6.0 arrays.
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probes within 2 kb of 95% of the known genes and, on
average, >9 probes per gene. Therefore, although the Infi-
nium arrays may lack the resolution of SNP arrays to de-
tect alterations in large intergenic regions or gene desert
regions, they provide high resolution coverage of the ma-
jority of coding loci. This allows for the identification of
discreet alterations of individual genes, which would not
be detected by standard SNP arrays. Similarly, with over
94% of CpG islands represented, these arrays may also
allow the identification of small alterations within regula-
tory regions, potentially revealing novel mechanisms of
gene disregulation. Therefore, the gene-centric/biased de-
sign of the Infinium array has a greater potential to iden-
tify driver CNAs involved in tumorigenic processes.
Furthermore, as the same loci can be interrogated for
both methylation and CN in the same DNA sample, the
analysis potentially allows easier integration of epigenetic
and genomic data. The integration of methylation and CN
data can provide fascinating insights into the underlying
biology of malignant processes where the challenge is to
identify driver from passenger alterations [3]. For instance,
a change in genomic content (that is, single copy gain or
loss) does not have to correlate with a linear change in
methylation; in fact, it is those genes that show an inverse
correlation between CNA and methylation that may be
most important. For example, tumor suppressor genes
that undergo a double hit - that is, heterozygous loss and
hypermethylation - or oncogenes in a region of gain that
are hypomethylated compared with neighboring genes
may represent those genes most likely to be differentially
expressed and consequently drivers of tumorigenic pro-
cesses. Hence, through utilizing the Infinium arrays for
both epigenetic and CN analysis, it may be possible to
more accurately distinguish between genes that drive the
selection of a malignant phenotype from those that are
passengers within an amplified or deleted region.
Finally, it can be difficult to compare CNA data across
different high-density array platforms, particularly given
Figure 8 Infinium unique GSTT1 deletion. CN profiles for a proportion of chromosome 22 for a single chondrosarcoma sample generated from
Infinium HumanMethylation450 BeadChip (upper panel) and CytoSNP arrays (middle panel). The Infinium array specific deletion of GSTT1 is
highlighted (blue box). The lower panel shows the genomic organization of the Infinium unique GSTT1 region of deletion and the distribution of
probes on the Infinium methylation, CytoSNP and SNP 6.0 arrays.
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differing designs, and even the comparison of the same
data with differing algorithms can lead to varying results
[37-39]. Even given these caveats, these data show the util-
ity of using the Infinium HumanMethylation450 Bead-
Chips to define CNAs in human cancers. We show that
the Infinium Arrays are as robust and sensitive as current
high density SNP arrays for the detection of CNAs and
appear highly applicable for providing estimates of CN as
well as a measure of methylation state. Furthermore, we
highlight that the gene centric design of the arrays may be
beneficial, in allowing the identification of alterations con-
taining single genes or just regulatory regions, which may
aid in our understanding of the complex genomic and epi-
genomic interactions driving the development and pro-
gression of a malignant phenotype.
Materials and methods
Study population
DNA from 11 chondrosarcoma specimens were subjected to
profiling on Infinium HumanMethylation450 BeadChip and
HumanCytoSNP-12 BeadChip (GSE40853) [40]. The mater-
ial was obtained from the RNOH Musculoskeletal Biobank,
with approval provided by the Cambridgeshire 1 Research
Ethics Committee (reference number 09/H0304/78).
Infinium methylation data with matched targeted exome-
seq data were generated from 44 formalin-fixed paraffin
wax-embedded (FFPE) head and neck squamous cell car-
cinoma (HNSCC) samples [41] (GSE38271, SRP034519).
Ethical approval for these samples was granted by the UCL/
UCLH Ethics Committee (reference number 04/Q0505/59).
Finally, matched Infinium array and Affymetrix SNP6.0
array data were downloaded from TCGA DataPortal for
74 GBM samples [42] and for 178 prostate cancer samples
[43].
Genome-wide methylation profiling
For chondrosarcoma and HNSCC, 1 μg of DNA from fresh
frozen tissue and 2 μg from FFPE tissues [41] were bisulfite
converted using the EZ DNA Methylation kit (Zymo Re-
search Corp. Irvine, CA, USA) according to the manufac-
turers instructions, with the exception of FFPE samples,
which were bisulfite converted using a modified protocol
[44]. Bisulphite converted samples were processed and hy-
bridized to the Infinium HumanMethylation450 BeadChip
according to the manufacturers recommendations. Subse-
quent data were processed and beta values computed using
the methylation module of the GenomeStudio software
(version 1.9.0; Illumina). Briefly, each CpG locus interro-
gated is represented by signals corresponding to both the
methylated (M) and unmethylated (U) alleles, respectively.
The beta value represents the ratio of the intensity of the
methylated bead type to the combined locus intensity: β =
max(M, 0)/(max(M,0) +max(U,0) + 100) and reflects the
methylation status of a specific CpG site.
CytoSNP
DNA (300 ng) from 11 chondrosarcoma specimens and
one normal reference DNA sample were processed and
hybridized to the HumanCytoSNP-12 BeadChip according
to the manufacturers instructions. Subsequent data were
processed and R values computed using the genotyping
module of the GenomeStudio software (version 1.9.0; Illu-
mina). Further analysis and identification of CNAs was
carried out in R (version 2.15.0) [45].
Identification of copy number alterations
CNA data were generated from un-normalized signal in-
tensities. Signal intensities were extracted for each sample
using GenomeStudio. Probe intensities were subsequently
subjected to GC content normalization, carried out using
cyclic loess and log2 ratios, generated to averaged normal
reference samples [25]. Circular binary segmentation,
from the R package DNAcopy, was then performed to de-
fine chromosomal segments with differing CN states, with
the following settings: alpha = 0.001, undo.splits = sdundo,
min.wdith = 3 [31]. Thresholds for the identification of
single copy CNAs were derived from the difference in log
ratio between normal reference DNA from male and
female samples (log2 ± 0.33), denoting a single copy
change in the X chromosome; high-level amplifications
and homozygous deletions were defined incrementally
from this threshold. The level of noise was determined
from the median deviance of neighboring probes. Probes
that show a high degree of variability, such as the highly
polymorphic major histocompatibility (MHC) region on
the short arm of chromosome 6, were removed from sub-
sequent analysis.
This method for identifying CNAs from the Infinium
methylation arrays is incorporated in the ChAMP Bio-
conductor package [46,47], an Infinium HumanMethyla-
tion450K array integrated analysis pipeline that allows
quality control, normalization, calling of differentially
methylated regions and methylation variable positions
along with detection of CNAs [47].
Copy number alterations from reference CytoSNP arrays
were generated with DNAcopy (chondrosarcomas) as
above from normalized R values. We analyzed publicly
available GBM Affymetrix SNP6.0 segmented data to iden-
tify CNAs. Thresholds derived from the difference between
sex chromosomes in male and female patients was used to
identify single CN gains and homozygous deletions. Ampli-
fications and homozygous deletions were assessed using in-
cremental thresholds.
Correlation between Infinium and SNP array-defined
CNAs
Regression analysis was used to determine the association
between signal intensities and CNAs from the Infinium
HumanMethylation450 BeadChip and CNA status defined
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from SNP arrays (Affymetrix SNP6.0 or Illumina CytoSNP).
This was carried out in R using Bioconductor packages glm
or gam. The Bioconductor packages and iRanges [48] were
used to define overlapping regions between Infinium and
SNP array CNA data from all 407 paired samples.
Binomial probabilities of true positive detection were
calculated across all 407 samples at any given CNA al-
teration threshold (deletion, loss, gain or amplification).
We define true positive binomial probabilities first by
defining true positive counts. The true positive count is
defined as the number of overlapping regions between
paired samples on any two platforms at any given alter-
ation threshold and alteration size. A binomial test was
used to convert true positive counts to binomial prob-
abilities with 95% confidence intervals for each sample
comparison.
Sensitivity was defined by the number of true positives
over the total number of alterations (true positives plus
false negatives) detected by the Infinium array at any
given alteration threshold. Specificity was determined by
the Infinium false positive call rate (that is, an Infinium
CNA identified in a region of no change defied by the
SNP array). True negatives were defined as overlapping
genomic regions without alteration on both platforms,
compared to the number of Infinium false positives plus
true negatives. Only windows with more than three
probes in both platforms were assessed.
Targeted exome sequence analysis
Matched tumor and germline DNA from 44 FFPE
HNSCC samples were subjected to targeted exome cap-
ture and next-generation sequencing [36,41]. Briefly, ex-
ome sequencing was carried out using a custom
SureSelect capture kit, representing 3,230 exons in 182
cancer-related genes plus 37 introns from 14 genes often
rearranged in cancer. Paired-end sequencing was per-
formed using the HiSeq2000 (Illumina). Reads were subse-
quently mapped to the reference human genome (hg19)
using the BWA aligner and processed using SAMtools
[49], Picard [50] and the Genome Analysis Toolkit
(GATK) [51]. CNAs were detected by comparing targeted
genomic DNA sequence coverage with a process-matched
normal control sample. Genomic rearrangements were
detected by clustering chimeric reads mapping to targeted
introns [36,47].
Quantitative PCR validation of alterations
Deletions of PTCH1 (chromosome 9) and GSTT1 (chromo-
some 22) were validated in triplicate biological replicates
using SYBR-Green quantitative PCR. Loss of these regions
was determined relative to the control gene ACTB
(chromosome 7), a universal housekeeping gene.
Additional file
Additional file 1: Figures S1 to S5. Figure S1. Distribution of beta
values for promoter associated and non-associated CpGs. (A) Boxplot of
beta values for CpGs in non-CpG island associated promoters and CpG is-
land associated promoters for regions of genomic amplification. (B)
Regions of genomic deletion, (C) Regions of genomic loss, (D) CNA neutral
regions and (E) Regions of single copy gain.
Abbreviations
CN: copy number; CNA: copy number alteration; GBM: glioblastoma
multiforme; HNSCC: head and neck squamous cell carcinoma;
ICGC: International Cancer Genome Consortium; SNP: single-nucleotide
polymorphism; TCGA: The Cancer Genome Atlas.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
AF conceived and developed the method for identifying CNAs from Infinium
arrays and wrote the manuscript. TJM incorporated the method in the
ChAMP pipeline. GAW and AET provided bioinformatics and statistical
support. ML, PG, TF, and AMF provided samples and data. SB and JDK
supervised the study and CT, SB and JDK contributed to writing the
manuscript. All authors have read and approved the final manuscript.
Acknowledgments
AF is supported by the UCL/UCLH Comprehensive Biomedical Research
Centre and the Rosetrees Trust. Research in the Beck lab was supported by
the Wellcome Trust (WT084071, WT093855), Royal Society Wolfson Research
Merit Award (WM100023), MRC (G100041), IMI-JU OncoTrack (115234) and
EU-FP7 projects EPIGENESYS (257082), IDEAL (259679) and BLUEPRINT
(282510). PG was supported by a PhD CASE Studentship from the UK Medical
Research Council (G1000411). CT is supported by Cancer Research UK and The
Raymond and Beverly Sackler Foundation. AET was supported by a Heller
Research Fellowship. Research in the Flanagan lab was supported by Skeletal
Cancer Action Trust (Scat), the UCLH/UCL Comprehensive Biomedical Research
Programme and the UCL Experimental Cancer Centre. JK is supported by the
UCLH/UCL Comprehensive Biomedical Research Programme.
Author details
1UCL Cancer Institute, University College London, 72 Huntley Street, London
WC1E 6BT, UK. 2Royal National Orthopaedic Hospital, Stanmore, Brockly Hill,
Middlesex HA7 4LP, UK. 3Division of Surgery and Interventional Science, UCL
Medical School, University College London, London WC1E 6BT, UK.
Received: 3 July 2013 Accepted: 3 February 2014
Published: 3 February 2014
References
1. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S,
Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R,
Foster CS, Cooper CS: Amplification and overexpression of E2F3 in human
bladder cancer. Oncogene 2004, 23:1627–1630.
2. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD,
Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ:
Comparative analyses of chromosome alterations in soft-tissue
metastases within and across patients with castration-resistant
prostate cancer. Cancer Res 2009, 69:7793–7802.
3. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA,
Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M,
Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK,
Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M:
Comprehensive genomic characterization of squamous cell lung cancers.
Nature 2012, 489:519–525.
4. Cancer Genome Atlas N: Comprehensive molecular portraits of human
breast tumours. Nature 2012, 490:61–70.
5. Kallioniemi A, Kallioniemi OP, Waldman FM, Chen LC, Yu LC, Fung YK, Smith HS,
Pinkel D, Gray JW: Detection of retinoblastoma gene copy number in
Feber et al. Genome Biology 2014, 15:R30 Page 11 of 13
http://genomebiology.com/2014/15/2/R30
metaphase chromosomes and interphase nuclei by fluorescence in situ
hybridization. Cytogenet Cell Genet 1992, 60:190–193.
6. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL,
Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG: High
resolution analysis of DNA copy number variation using comparative
genomic hybridization to microarrays. Nat Genet 1998, 20:207–211.
7. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G,
Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW,
Jain AN, Pinkel D, Albertson DG: Assembly of microarrays for genome-wide
measurement of DNA copy number. Nat Genet 2001, 29:263–264.
8. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J,
Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M: An integrated view
of copy number and allelic alterations in the cancer genome using
single nucleotide polymorphism arrays. Cancer Res 2004, 64:3060–3071.
9. Haraksingh RR, Abyzov A, Gerstein M, Urban AE, Snyder M: Genome-wide
mapping of copy number variation in humans: comparative analysis of
high resolution array platforms. PLoS One 2011, 6:e27859.
10. Fridley BL, Chalise P, Tsai YY, Sun Z, Vierkant RA, Larson MC, Cunningham JM,
Iversen ES, Fenstermacher D, Barnholtz-Sloan J, Asmann Y, Risch HA, Schildkraut JM,
Phelan CM, Sutphen R, Sellers TA, Goode EL: Germline copy number variation and
ovarian cancer survival. Front Genet 2012, 3:142.
11. McCarroll SA: Extending genome-wide association studies to
copy-number variation. Hum Mol Genet 2008, 17:R135–R142.
12. Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Graf S, Johnson N,
Herrero J, Tomazou EM, Thorne NP, Backdahl L, Herberth M, Howe KL,
Jackson DK, Miretti MM, Marioni JC, Birney E, Hubbard TJ, Durbin R, Tavare S,
Beck S: A Bayesian deconvolution strategy for immunoprecipitation-based
DNA methylome analysis. Nat Biotechnol 2008, 26:779–785.
13. Feber A, Wilson GA, Zhang L, Presneau N, Idowu B, Down TA, Rakyan VK,
Noon LA, Lloyd AC, Stupka E, Schiza V, Teschendorff AE, Schroth GP,
Flanagan A, Beck S: Comparative methylome analysis of benign and
malignant peripheral nerve sheath tumors. Genome Res 2011,
21:515–524.
14. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D:
Chromosome-wide and promoter-specific analyses identify sites of
differential DNA methylation in normal and transformed human cells.
Nat Genet 2005, 37:853–862.
15. Irizarry RA, Ladd-Acosta C, Carvalho B, Wu H, Brandenburg SA, Jeddeloh JA,
Wen B, Feinberg AP: Comprehensive high-throughput arrays for relative
methylation (CHARM). Genome Res 2008, 18:780–790.
16. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL:
Genome-wide DNA methylation profiling using Infinium assay.
Epigenomics 2009, 1:177–200.
17. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L,
Schroth GP, Gunderson KL, Fan JB, Shen R: High density DNA methylation
array with single CpG site resolution. Genomics 2011, 98:288–295.
18. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ,
Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J,
Fan JB: High-throughput DNA methylation profiling using universal bead
arrays. Genome Res 2006, 16:383–393.
19. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E,
Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S,
McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M,
Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z,
Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched
evolution revealed by multiregion sequencing. N Engl J Med 2012,
366:883–892.
20. Houseman EA, Christensen BC, Karagas MR, Wrensch MR, Nelson HH, Wiemels JL,
Zheng S, Wiencke JK, Kelsey KT, Marsit CJ: Copy number variation has little
impact on bead-array-based measures of DNA methylation. Bioinformatics
2009, 25:1999–2005.
21. Kwee I, Rinaldi A, Rancoita P, Rossi D, Capello D, Forconi F, Giuliani N, Piva R,
Inghirami G, Gaidano G, Zucca E, Bertoni F: Integrated DNA copy number
and methylation profiling of lymphoid neoplasms using a single array.
Br J Haematol 2012, 156:354–357.
22. Miller CA, Hampton O, Coarfa C, Milosavljevic A: ReadDepth: a parallel R
package for detecting copy number alterations from short sequencing
reads. PLoS One 2011, 6:e16327.
23. Letouze E, Allory Y, Bollet MA, Radvanyi F, Guyon F: Analysis of the copy
number profiles of several tumor samples from the same patient reveals
the successive steps in tumorigenesis. Genome Biol 2010, 11:R76.
24. Deaton AM, Bird A: CpG islands and the regulation of transcription.
Genes Dev 2011, 25:1010–1022.
25. Marioni JC, Thorne NP, Valsesia A, Fitzgerald T, Redon R, Fiegler H, Andrews TD,
Stranger BE, Lynch AG, Dermitzakis ET, Carter NP, Tavare S, Hurles ME: Breaking
the waves: improved detection of copy number variation from microarray-
based comparative genomic hybridization. Genome Biol 2007, 8:R228.
26. Diskin SJ, Li M, Hou C, Yang S, Glessner J, Hakonarson H, Bucan M, Maris JM,
Wang K: Adjustment of genomic waves in signal intensities from whole-
genome SNP genotyping platforms. Nucleic Acids Res 2008, 36:e126.
27. Sun Z, Chai HS, Wu Y, White WM, Donkena KV, Klein CJ, Garovic VD, Therneau TM,
Kocher JP: Batch effect correction for genome-wide methylation data with Illu-
mina Infinium platform. BMC Med Genomics 2011, 4:84.
28. Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerstrom-Billai F,
Jagodic M, Sundberg CJ, Ekstrom TJ, Teschendorff AE, Tegner J,
Gomez-Cabrero D: An evaluation of analysis pipelines for DNA
methylation
profiling using the Illumina HumanMethylation450 BeadChip
platform. Epigenetics 2013, 8:333–346.
29. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 2007,
8:118–127.
30. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F:
Evaluation of the Infinium Methylation 450 K technology. Epigenomics 2011,
3:771–784.
31. Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary
segmentation for the analysis of array-based DNA copy number data.
Biostatistics 2004, 5:557–572.
32. Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, Emami M, Sugar L,
Sweet J, Toi A, Narod SA: The use of genetic markers to determine risk for
prostate cancer at prostate biopsy. Clin Cancer Res 2005, 11:8391–8397.
33. Choubey VK, Sankhwar SN, Tewari R, Sankhwar P, Singh BP, Rajender S:
Null genotypes at the GSTM1 and GSTT1 genes and the risk of benign
prostatic hyperplasia: A case–control study and a meta-analysis. Prostate
2012, 73:146–152.
34. Salinas-Souza C, Petrilli AS, de Toledo SR: Glutathione S-transferase
polymorphisms in osteosarcoma patients. Pharmacogenet Genomics 2010,
20:507–515.
35. Salinas-Sanchez AS, Sanchez-Sanchez F, Donate-Moreno MJ, Rubio-Del-Campo A,
Serrano-Oviedo L, Gimenez-Bachs JM, Martinez-Sanchiz C, Segura-Martin M,
Escribano J: GSTT1, GSTM1, and CYP1B1 gene polymorphisms and
susceptibility to sporadic renal cell cancer. Urol Oncol 2011, 30:864–870.
36. Lechner M, Frampton G, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M,
Cronin MT, Lipson D, Miller VA, Brennan TA, Henderson S, Vaz F, OF P,
Kalavrezos N, Yelenski R, Beck S, Stephens PJ, Boshoff C: Targeted next-
generation sequencing of head and neck squamous cell carcinoma
identifies novel genetic alterations in HPV+ and HPV- tumors.
Genome Med 2013, 5:49.
37. Eckel-Passow JE, Atkinson EJ, Maharjan S, Kardia SL, De AM: Software
comparison for evaluating genomic copy number variation for
Affymetrix 6.0 SNP array platform. BMC Bioinformatics 2011, 12:220.
38. Winchester L, Yau C, Ragoussis J: Comparing CNV detection methods for
SNP arrays. Brief Funct Genomic Proteomic 2009, 8:353–366.
39. Baross A, Delaney AD, Li HI, Nayar T, Flibotte S, Qian H, Chan SY, Asano J,
Ally A, Cao M, Birch P, Brown-John M, Fernandes N, Go A, Kennedy G,
Langlois S, Eydoux P, Friedman JM, Marra MA: Assessment of algorithms
for high throughput detection of genomic copy number variation in
oligonucleotide microarray data. BMC Bioinformatics 2007, 8:368.
40. Guilhamon P, Eskandarpour M, Halai D, Wilson GA, Feber A, Teschendorff AE,
Gomez V, Hergovich A, Tirabosco R, Fernanda Amary M, Baumhoer D, Jundt G,
Ross MT, Flanagan AM, Beck S: Meta-analysis of IDH-mutant cancers identifies
EBF1 as an interaction partner for TET2. Nat Commun 2013, 4:2166.
41. Lechner M, Fenton T, West J, Wilson G, Feber A, Henderson S, Thirlwell C,
Dibra HK, Jay A, Butcher L, Chakravarthy AR, Gratrix F, Patel N, Vaz F, O'Flynn P,
Kalavrezos N, Teschendorff AE, Boshoff C, Beck S: Identification and functional
validation of HPV-mediated hypermethylation in head and neck squamous
cell carcinoma. Genome Med 2013, 5:15.
42. The Cancer Genome Atlas: GBM. [https://tcga-data.nci.nih.gov/tcga/
tcgaCancerDetails.jsp?diseaseType=GBM&diseaseName]
43. The Cancer Genome Atlas: Prostate. [https://tcga-data.nci.nih.gov/tcga/
tcgaCancerDetails.jsp?diseaseType=PRAD&diseaseName=Prostate%
20adenocarcinoma]
Feber et al. Genome Biology 2014, 15:R30 Page 12 of 13
http://genomebiology.com/2014/15/2/R30
44. Thirlwell C, Eymard M, Feber A, Teschendorff A, Pearce K, Lechner M,
Widschwendter M, Beck S: Genome-wide DNA methylation analysis of
archival formalin-fixed paraffin-embedded tissue using the Illumina
Infinium HumanMethylation27 BeadChip. Methods 2010, 52:248–254.
45. The R project for statistical computing. [http://www.r-project.org/]
46. Bioconductor. [http://www.bioconductor.org/]
47. Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz
TK, Beck S: ChAMP: 450 k Chip Analysis Methylation Pipeline.
Bioinformatics 2013, 30:428–430.
48. Bioconductor: cghMRC. [http://www.bioconductor.org/packages/2.12/bioc/
html/cghMCR.html]
49. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
Durbin R: The Sequence Alignment/Map format and SAMtools.
Bioinformatics 2009, 25:2078–2079.
50. Picard. [http://picard.sourceforge.net]
51. Genome Analysis Toolkit. [https://www.broadinstitute.org/gatk/index.php]
doi:10.1186/gb-2014-15-2-r30
Cite this article as: Feber et al.: Using high-density DNA methylation
arrays to profile copy number alterations. Genome Biology 2014 15:R30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Feber et al. Genome Biology 2014, 15:R30 Page 13 of 13
http://genomebiology.com/2014/15/2/R30
